INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study
复制标题
DOI：
10.2217/imt-2018-0080
复制
发表时间：
2018-10-01
期刊：
影响因子：
2.8
通讯作者：
Buti, Sebastiano
中科院分区：
文献类型：
--
作者：
Bersanelli, Melissa;Giannarelli, Diana;Buti, Sebastiano
目的：考虑到对接受免疫检查点抑制剂(CKI)治疗的癌症患者进行流感疫苗接种咨询的需求尚未得到满足，计划进行一项探索性研究，以评估该人群的流感疫苗效果。方法：Invidia是一项多中心的回顾性研究，招募了在2016-2017流感季节接受CKI治疗的连续晚期癌症门诊患者。结果：在300名患者中，79人接种了流感疫苗。接种疫苗组流感综合征的发生率为24.1%，对照组为11.8%；优势比：2.4；95%可信区间：1.23-4.59；p=0.009。疫苗临床无效在老年人中更为明显：接种疫苗的患者为37.8%，未接种的患者为6.1%，优势比：9.28；95%的可信区间：2.77-31.14；P
Aim: Considering the unmet need for the counseling of cancer patients treated with immune checkpoint inhibitors (CKI) about influenza vaccination, an explorative study was planned to assess flu vaccine efficacy in this population. Methods: INVIDIa was a retrospective, multicenter study, enrolling consecutive advanced cancer outpatients receiving CKI during the influenza season 2016-2017. Results: Of 300 patients, 79 received flu vaccine. The incidence of influenza syndrome was 24.1% among vaccinated, versus 11.8% of controls; odds ratio: 2.4; 95% CI: 1.23-4.59; p=0.009. The clinical ineffectiveness of vaccine was more pronounced among elderly: 37.8% among vaccinated patients, versus 6.1% of unvaccinated, odds ratio: 9.28; 95% CI: 2.77-31.14; p